ea0007oc30 | Endocrine tumours | BES2004
Powles R
, Sirohi B
, Das M
, Kulkarni S
, Treleaven J
, Dearden C
, Morgan G
, McCormack R
, Wass J
Patients with haematological malignancies receiving neutropenia inducing chemotherapy sometimes have delayed discharge because of debility relating to complications of treatment. We assessed if these problems could be reduced by human growth hormone (GH) and also if haemopoetic recovery was quicker because stem cells have receptors for GH. In a randomized, double blind, placebo-controlled, trial patients were assigned to receive either GH, 250 mcg BD (n =75) or placebo (n =75)...